Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewPregnenolone sulfate sodium salt
Description: NMDA potentiator; also GABAA inhibitor and TRPM3 activator
Chemical Name: (3β)-3-(Sulfooxy)-pregn-5-en-20-one sodium salt
Biological Activity for Pregnenolone sulfate sodium salt
Pregnenolone sulfate sodium salt is a highly potent neurosteroid with multiple actions. Enhances intracellular Ca2+ upon NMDA receptor-mediated synaptic activity (EC50 ~ 2 pM) and potentiates NMDA responses. Inhibitor at GABAA receptors (IC50 values are 0.4 to >300 μM, depending on specific subunit conformation). Activates CREB phosphorylation, augments LTP and cognitive behavior in rat memory models. Also activates TRPM3 channels.
Technical Data for Pregnenolone sulfate sodium salt
| M. Wt | 418.52 |
| Formula | C21H31NaO5S |
| Storage | Store at +4°C |
| CAS Number | 1852-38-6 |
| PubChem ID | 23676306 |
| InChI Key | QQVJEIZJHDPTSH-UTNKIXDHSA-M |
| Smiles | O=[C@](C)[C@H]4CC[C@@]3([H])[C@]2([H])CC=C1C[C@@H](OS(=O)([O-])=O)CC[C@@](C)1[C@]([H])2CC[C@@]34C.[Na+] |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for Pregnenolone sulfate sodium salt
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 20.93 | 50 |
Preparing Stock Solutions for Pregnenolone sulfate sodium salt
The following data is based on the product molecular weight 418.52. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 0.5 mM | 4.78 mL | 23.89 mL | 47.79 mL |
| 2.5 mM | 0.96 mL | 4.78 mL | 9.56 mL |
| 5 mM | 0.48 mL | 2.39 mL | 4.78 mL |
| 25 mM | 0.1 mL | 0.48 mL | 0.96 mL |
Molarity Calculator
Molarity Calculator
Calculate the mass, volume, or concentration required for a solution.
Reconstitution Calculator
Reconstitution Calculator
Dilution Calculator
Dilution Calculator
Calculate the dilution required to prepare a stock solution.
Product Datasheets for Pregnenolone sulfate sodium salt
References for Pregnenolone sulfate sodium salt
References are publications that support the biological activity of the product.
Li et al (2007) Neuroactive steroids and human recombinant rho1 GABAC receptors. J.Pharmacol.Exp.Ther. 323 236 PMID: 17636008
Majeed et al (2010) Cis-isomerism and other chemical requirements of steroidal agonists and partial agonists acting at TRPM3 channels. Br.J.Pharmacol. 161 430 PMID: 20735426
Smith et al (2014) A role for picomolar concentrations of pregnenolone sulfate in synaptic activity-dependent Ca2+ signaling and CREB activation. Mol.Pharmacol. 86 390 PMID: 25057049
Seljeset et al (2018) Probing GABAA receptors with inhibitory neurosteroids. Neuropharmacology 136 23 PMID: 29447845
If you know of a relevant reference for Pregnenolone sulfate sodium salt, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Pregnenolone sulfate sodium salt, Pregnenolone sulfate sodium salt supplier, neuroactive, steroids, highly, potent, NMDA, TRPM3, memory, LTP, potentiators, activates, activators, GABA, Receptors, TRPM, GABAA, 5376, Tocris Bioscience
1 Citation for Pregnenolone sulfate sodium salt
Citations are publications that use Tocris products. Selected citations for Pregnenolone sulfate sodium salt include:
Luoma et al (2011) Progesterone inhibition of voltage-gated calcium channels is a potential neuroprotective mechanism against excitotoxicity. Steroids 76 845 PMID: 21371490
Do you know of a great paper that uses Pregnenolone sulfate sodium salt from Tocris? Please let us know.
Reviews for Pregnenolone sulfate sodium salt
There are currently no reviews for this product. Be the first to review Pregnenolone sulfate sodium salt and earn rewards!
Have you used Pregnenolone sulfate sodium salt?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Huntington's Disease Research Product Guide
This product guide provides a background to Huntington's disease research and lists around 100 products for the study of:
- Somatic Instability
- Proteolysis and Inclusion Bodies
- Transcriptional Dysregulation
- Mitochondrial Dysfunction
- Nuclear-Cytoplasmic Transport Interference
- Excitotoxicity
- Stem Cells
Alzheimer's Disease Poster
Alzheimer's disease (AD) is a debilitating and progressive neurodegenerative disease and the most common cause of dementia, affecting approximately 30% of individuals aged over 85 years. This poster summarizes the cellular and molecular mechanisms of AD.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's Disease Poster
Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.